Related Experiment Video
Updated: May 16, 2026

Assessment of Dependence in Activities of Daily Living Among Older Patients in an Acute Care Unit
Published on: September 30, 2020
How to maintain patients on long-term therapy: understanding the profile and kinetics of adverse events
1Hematology Department, University Hospital of Salamanca, Salamanca, Spain. mvmateos@usal.es
Abstract:
Thalidomide, lenalidomide, and bortezomib have considerably improved the survival of patients with multiple myeloma. These agents have specific adverse event (AE) profiles, and it is especially important to consider severe AEs that may lead to premature discontinuation, negatively affecting outcomes. AEs of particular concern are peripheral neuropathy (associated with thalidomide and bortezomib), venous thromboembolism (associated with thalidomide and lenalidomide), and myelosuppression (associated with lenalidomide and bortezomib). AEs are usually predictable and easily managed with monitoring, appropriate dose adjustments, and supportive care. AEs are generally transient, occurring early in the course of treatment, providing evidence for the feasibility of continuous therapy.
Related Concept Videos
Drug Therapy
Antianxiety Medications
Nonlinear Pharmacokinetics: Overview
Nonlinearity can arise due to the saturation of plasma protein-binding or...
Therapeutic Drug Monitoring: Affecting Factors
Rational Dosage Regimen: Maintenance Dose and Loading Dose
In most cases, drugs are administered repetitively or infused continuously to maintain a steady-state concentration in the body. At a steady state,...
Drug Toxicity: Risk factors
Pharmacokinetic–Pharmacodynamic Relationship: Influence of Elimination Half-Life on Effect Duration